{
    "xml": "<topic id=\"PHP413\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/ranitidine\" basename=\"ranitidine\" title=\"RANITIDINE\">\n<title>RANITIDINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_747\" namespace=\"/interactions/list-of-drug-interactions/ulcer-healing-drugs/histamine-h2-antagonists/ranitidine\">Ranitidine</xref>\n</p>\n<data name=\"vtmid\">48174005</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_389169120\" title=\"H2-receptor antagonists\">H2-receptor antagonists</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34660\" title=\"H2-RECEPTOR ANTAGONISTS\" namespace=\"/drug-classes/h2-receptor-antagonists\">H2-RECEPTOR ANTAGONISTS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP62492\" outputclass=\"indicationsAndDose\" rev=\"1.42\" parent=\"/drugs/ranitidine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Benign gastric ulceration</p>\n<p outputclass=\"therapeuticIndication\">Duodenal ulceration</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;5 months</p>\n<p>1&#8239;mg/kg 3 times a day (max. per dose 3&#8239;mg/kg 3 times a day).</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 6 months&#8211;2 years</p>\n<p>2&#8211;4&#8239;mg/kg twice daily.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 3&#8211;11 years</p>\n<p>2&#8211;4&#8239;mg/kg twice daily (max. per dose 150&#8239;mg).</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>150&#8239;mg twice daily, alternatively 300&#8239;mg once daily, at night.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg twice daily, alternatively 300&#8239;mg once daily, at night.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Chronic episodic dyspepsia</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>150&#8239;mg twice daily for 6 weeks, alternatively 300&#8239;mg once daily for 6 weeks, dose to be taken at night.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg twice daily for 6 weeks, alternatively 300&#8239;mg once daily for 6 weeks, dose to be taken at night.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">NSAID-associated gastric ulceration</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>150&#8239;mg twice daily for up to 8 weeks, alternatively 300&#8239;mg once daily for up to 8 weeks, dose to be taken at night.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg twice daily for up to 8 weeks, alternatively 300&#8239;mg once daily for up to 8 weeks, dose to be taken at night.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">NSAID-associated duodenal ulcer</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>300&#8239;mg twice daily for 4 weeks, to achieve a higher healing rate.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>300&#8239;mg twice daily for 4 weeks, to achieve a higher healing rate.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of NSAID-associated gastric ulcer</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of NSAID-associated duodenal ulcer</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>300&#8239;mg twice daily.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>300&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Gastro-oesophageal reflux disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>150&#8239;mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300&#8239;mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300&#8239;mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Moderate to severe gastro-oesophageal reflux disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>600&#8239;mg daily in 2&#8211;4 divided doses for up to 12 weeks.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>600&#8239;mg daily in 2&#8211;4 divided doses for up to 12 weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Long-term treatment of healed gastro-oesophageal reflux disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 3&#8211;11 years</p>\n<p>2.5&#8211;5&#8239;mg/kg twice daily (max. per dose 300&#8239;mg).</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>150&#8239;mg twice daily.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Gastric acid reduction (prophylaxis of acid aspiration) in obstetrics</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>150&#8239;mg, dose to be given at onset of labour, then 150&#8239;mg every 6&#8239;hours.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>150&#8239;mg, dose to be given at onset of labour, then 150&#8239;mg every 6&#8239;hours.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Gastric acid reduction (prophylaxis of acid aspiration) in surgical procedures</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intramuscular injection or by slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8239;mg, to be given 45&#8211;60 minutes before induction of anaesthesia, intravenous injection diluted to 20&#8239;mL and given over at least 2 minutes, alternatively (by mouth) 150&#8239;mg, to be given 2 hours before induction of anaesthesia and also when possible on the preceding evening.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of stress ulceration</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8239;mg every 8&#8239;hours, dose to be diluted to 20&#8239;mL and given over at least 2 minutes, then (by mouth) 150&#8239;mg twice daily, may be given when oral feeding commences.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Reflux oesophagitis and other conditions where gastric acid reduction is beneficial</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;5 months</p>\n<p>1&#8239;mg/kg 3 times a day (max. per dose 3&#8239;mg/kg 3 times a day).</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 6 months&#8211;2 years</p>\n<p>2&#8211;4&#8239;mg/kg twice daily.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 3&#8211;11 years</p>\n<p>2&#8211;4&#8239;mg/kg twice daily (max. per dose 150&#8239;mg); increased to up to 5&#8239;mg/kg twice daily (max. per dose 300&#8239;mg), dose increase for severe gastro-oesophageal disease.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>150&#8239;mg twice daily, alternatively 300&#8239;mg once daily, dose to be taken at night, then increased if necessary to 300&#8239;mg twice daily for up to 12 weeks in moderate to severe gastro-oesophageal reflux disease, alternatively increased if necessary to 150&#8239;mg 4 times a day for up to 12 weeks in moderate to severe gastro-oesophageal reflux disease.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Conditions where reduction of gastric acidity is beneficial and oral route not available</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8239;mg every 6&#8211;8&#8239;hours.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>50&#8239;mg, dose to be diluted to 20&#8239;mL and given over at least 2 minutes; may be repeated every 6&#8211;8 hours.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62368\" outputclass=\"unlicensedUse\" rev=\"1.12\" parent=\"/drugs/ranitidine\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use in children</p>\n<p>\n<i>Oral</i> preparations not licensed for use in children under 3 years. </p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in children</p>\n<p>\n<i>Injection</i> not licensed for use in children under 6 months.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>Doses given for prophylaxis of NSAID-associated gastric or duodenal ulcer, and prophylaxis of stress ulceration, are not licensed.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62452\" outputclass=\"interactions\" rev=\"1.6\" parent=\"/drugs/ranitidine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (histamine H<sub>2</sub>-antagonists).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62394\" outputclass=\"sideEffects\" rev=\"1.6\" parent=\"/drugs/ranitidine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Blurred vision</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">interstitial nephritis</ph>; <ph outputclass=\"sideEffect\">involuntary movement disorders</ph>; <ph outputclass=\"sideEffect\">pancreatitis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62442\" outputclass=\"pregnancy\" parent=\"/drugs/ranitidine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless essential, but not known to be harmful.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62716\" outputclass=\"breastFeeding\" parent=\"/drugs/ranitidine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Significant amount present in milk, but not known to be harmful.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62413\" outputclass=\"renalImpairment\" parent=\"/drugs/ranitidine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>Use half normal dose if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>Use half normal dose if estimated glomerular filtration rate less than 50&#8239;mL/minute/1.73&#8239;m <sup>2</sup>.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62751\" outputclass=\"directionsForAdministration\" rev=\"1.10\" parent=\"/drugs/ranitidine\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in children</p>\n<p>For <i>slow intravenous injection</i> dilute to a concentration of 2.5&#8239;mg/mL with Glucose 5% or Sodium Chloride 0.9%; give over at least 3 minutes.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in adults</p>\n<p>For <i>intravenous infusion</i> (<i>Zantac</i>\n<tm tmtype=\"reg\"/>), give intermittently in Glucose 5% or Sodium Chloride 0.9%.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62426\" outputclass=\"patientAndCarerAdvice\" rev=\"1.18\" parent=\"/drugs/ranitidine\">\n<title>Patient and carer advice</title>\n<body>\r\n\r\n\r\n<section outputclass=\"patientResources\">\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">In children</p>\r\n<p outputclass=\"title\">Medicines for Children leaflet: Ranitidine for acid reflux</p>\r\n<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/ranitidine-for-acid-reflux\">www.medicinesforchildren.org.uk/ranitidine-for-acid-reflux</xref>\n</p>\n</sectiondiv>\n</section>\r\n<section outputclass=\"generalPatientAdvice\">\r\n<sectiondiv>\r\n<p>In fat malabsorption syndrome, give oral doses 1&#8211;2 hours before food to enhance effects of pancreatic enzyme replacement.</p>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP62332\" outputclass=\"exceptionsToLegalCategory\" rev=\"1.8\" parent=\"/drugs/ranitidine\">\n<title>Exceptions to legal category</title>\n<body>\n<section>\n<sectiondiv>\n<p>Ranitidine can be sold to the public for adults and children over 16 years (provided packs do not contain more than 2 weeks&#8217; supply) for the short-term symptomatic relief of heartburn, dyspepsia, and hyperacidity, and for the prevention of these symptoms when associated with consumption of food or drink (max. single dose 75&#8239;mg, max. daily dose 300&#8239;mg).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP413-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/ranitidine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension, oral solution, infusion</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76490\" title=\"Tablet\" namespace=\"/drugs/ranitidine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76643\" title=\"Effervescent tablet\" namespace=\"/drugs/ranitidine/effervescent-tablet\">Effervescent tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76799\" title=\"Oral solution\" namespace=\"/drugs/ranitidine/oral-solution\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76567\" title=\"Solution for injection\" namespace=\"/drugs/ranitidine/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78174\" namespace=\"/treatment-summaries/gastro-oesophageal-reflux-disease\" title=\"Gastro-oesophageal reflux disease\" count=\"1\" rel=\"backlink\">Gastro-oesophageal reflux disease</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78207\" namespace=\"/treatment-summaries/peptic-ulceration\" title=\"Peptic ulceration\" count=\"1\" rel=\"backlink\">Peptic ulceration</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_747\" namespace=\"/interactions/list-of-drug-interactions/ulcer-healing-drugs/histamine-h2-antagonists/ranitidine\" title=\"Ranitidine\" count=\"1\" rel=\"link\">Ranitidine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34660\" namespace=\"/drug-classes/h2-receptor-antagonists\" title=\"H2-RECEPTOR ANTAGONISTS\" count=\"1\" rel=\"link\">H2-RECEPTOR ANTAGONISTS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76490\" namespace=\"/drugs/ranitidine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76643\" namespace=\"/drugs/ranitidine/effervescent-tablet\" title=\"Effervescent tablet\" count=\"1\" rel=\"link\">Effervescent tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76799\" namespace=\"/drugs/ranitidine/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76567\" namespace=\"/drugs/ranitidine/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP413",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/ranitidine",
    "basename": "ranitidine",
    "title": "RANITIDINE",
    "interactants": [
        {
            "id": "bnf_int_747",
            "label": "Ranitidine"
        }
    ],
    "vtmid": "48174005",
    "drugClassification": [
        "H2-receptor antagonists"
    ],
    "inheritsFromClass": [
        "H2-RECEPTOR ANTAGONISTS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Benign gastric ulceration",
                        "html": "Benign gastric ulceration"
                    },
                    {
                        "textContent": "Duodenal ulceration",
                        "html": "Duodenal ulceration"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "1 mg/kg 3 times a day (max. per dose 3 mg/kg 3 times a day).",
                        "html": "<p>1&#8239;mg/kg 3 times a day (max. per dose 3&#8239;mg/kg 3 times a day).</p>",
                        "ageGroup": "1&#8211;5 months"
                    },
                    {
                        "textContent": "2&#8211;4 mg/kg twice daily.",
                        "html": "<p>2&#8211;4&#8239;mg/kg twice daily.</p>",
                        "ageGroup": "6 months&#8211;2 years"
                    },
                    {
                        "textContent": "2&#8211;4 mg/kg twice daily (max. per dose 150 mg).",
                        "html": "<p>2&#8211;4&#8239;mg/kg twice daily (max. per dose 150&#8239;mg).</p>",
                        "ageGroup": "3&#8211;11 years"
                    },
                    {
                        "textContent": "150 mg twice daily, alternatively 300 mg once daily, at night.",
                        "html": "<p>150&#8239;mg twice daily, alternatively 300&#8239;mg once daily, at night.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "150 mg twice daily, alternatively 300 mg once daily, at night.",
                        "html": "<p>150&#8239;mg twice daily, alternatively 300&#8239;mg once daily, at night.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Chronic episodic dyspepsia",
                        "html": "Chronic episodic dyspepsia"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "150 mg twice daily for 6 weeks, alternatively 300 mg once daily for 6 weeks, dose to be taken at night.",
                        "html": "<p>150&#8239;mg twice daily for 6 weeks, alternatively 300&#8239;mg once daily for 6 weeks, dose to be taken at night.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "150 mg twice daily for 6 weeks, alternatively 300 mg once daily for 6 weeks, dose to be taken at night.",
                        "html": "<p>150&#8239;mg twice daily for 6 weeks, alternatively 300&#8239;mg once daily for 6 weeks, dose to be taken at night.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "NSAID-associated gastric ulceration",
                        "html": "NSAID-associated gastric ulceration"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "150 mg twice daily for up to 8 weeks, alternatively 300 mg once daily for up to 8 weeks, dose to be taken at night.",
                        "html": "<p>150&#8239;mg twice daily for up to 8 weeks, alternatively 300&#8239;mg once daily for up to 8 weeks, dose to be taken at night.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "150 mg twice daily for up to 8 weeks, alternatively 300 mg once daily for up to 8 weeks, dose to be taken at night.",
                        "html": "<p>150&#8239;mg twice daily for up to 8 weeks, alternatively 300&#8239;mg once daily for up to 8 weeks, dose to be taken at night.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "NSAID-associated duodenal ulcer",
                        "html": "NSAID-associated duodenal ulcer"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "300 mg twice daily for 4 weeks, to achieve a higher healing rate.",
                        "html": "<p>300&#8239;mg twice daily for 4 weeks, to achieve a higher healing rate.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "300 mg twice daily for 4 weeks, to achieve a higher healing rate.",
                        "html": "<p>300&#8239;mg twice daily for 4 weeks, to achieve a higher healing rate.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of NSAID-associated gastric ulcer",
                        "html": "Prophylaxis of NSAID-associated gastric ulcer"
                    },
                    {
                        "textContent": "Prophylaxis of NSAID-associated duodenal ulcer",
                        "html": "Prophylaxis of NSAID-associated duodenal ulcer"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "300 mg twice daily.",
                        "html": "<p>300&#8239;mg twice daily.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "300 mg twice daily.",
                        "html": "<p>300&#8239;mg twice daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Gastro-oesophageal reflux disease",
                        "html": "Gastro-oesophageal reflux disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "150 mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300 mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night.",
                        "html": "<p>150&#8239;mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300&#8239;mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "150 mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300 mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night.",
                        "html": "<p>150&#8239;mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300&#8239;mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Moderate to severe gastro-oesophageal reflux disease",
                        "html": "Moderate to severe gastro-oesophageal reflux disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "600 mg daily in 2&#8211;4 divided doses for up to 12 weeks.",
                        "html": "<p>600&#8239;mg daily in 2&#8211;4 divided doses for up to 12 weeks.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "600 mg daily in 2&#8211;4 divided doses for up to 12 weeks.",
                        "html": "<p>600&#8239;mg daily in 2&#8211;4 divided doses for up to 12 weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Long-term treatment of healed gastro-oesophageal reflux disease",
                        "html": "Long-term treatment of healed gastro-oesophageal reflux disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "2.5&#8211;5 mg/kg twice daily (max. per dose 300 mg).",
                        "html": "<p>2.5&#8211;5&#8239;mg/kg twice daily (max. per dose 300&#8239;mg).</p>",
                        "ageGroup": "3&#8211;11 years"
                    },
                    {
                        "textContent": "150 mg twice daily.",
                        "html": "<p>150&#8239;mg twice daily.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "150 mg twice daily.",
                        "html": "<p>150&#8239;mg twice daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Gastric acid reduction (prophylaxis of acid aspiration) in obstetrics",
                        "html": "Gastric acid reduction (prophylaxis of acid aspiration) in obstetrics"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "150 mg, dose to be given at onset of labour, then 150 mg every 6 hours.",
                        "html": "<p>150&#8239;mg, dose to be given at onset of labour, then 150&#8239;mg every 6&#8239;hours.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "150 mg, dose to be given at onset of labour, then 150 mg every 6 hours.",
                        "html": "<p>150&#8239;mg, dose to be given at onset of labour, then 150&#8239;mg every 6&#8239;hours.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Gastric acid reduction (prophylaxis of acid aspiration) in surgical procedures",
                        "html": "Gastric acid reduction (prophylaxis of acid aspiration) in surgical procedures"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intramuscular injection or slow intravenous injection"
                    ],
                    "textContent": "Initially by intramuscular injection or by slow intravenous injection",
                    "html": "Initially by intramuscular injection or by slow intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "50 mg, to be given 45&#8211;60 minutes before induction of anaesthesia, intravenous injection diluted to 20 mL and given over at least 2 minutes, alternatively (by mouth) 150 mg, to be given 2 hours before induction of anaesthesia and also when possible on the preceding evening.",
                        "html": "<p>50&#8239;mg, to be given 45&#8211;60 minutes before induction of anaesthesia, intravenous injection diluted to 20&#8239;mL and given over at least 2 minutes, alternatively (by mouth) 150&#8239;mg, to be given 2 hours before induction of anaesthesia and also when possible on the preceding evening.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of stress ulceration",
                        "html": "Prophylaxis of stress ulceration"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially slow intravenous injection"
                    ],
                    "textContent": "Initially by slow intravenous injection",
                    "html": "Initially by slow intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "50 mg every 8 hours, dose to be diluted to 20 mL and given over at least 2 minutes, then (by mouth) 150 mg twice daily, may be given when oral feeding commences.",
                        "html": "<p>50&#8239;mg every 8&#8239;hours, dose to be diluted to 20&#8239;mL and given over at least 2 minutes, then (by mouth) 150&#8239;mg twice daily, may be given when oral feeding commences.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Reflux oesophagitis and other conditions where gastric acid reduction is beneficial",
                        "html": "Reflux oesophagitis and other conditions where gastric acid reduction is beneficial"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "1 mg/kg 3 times a day (max. per dose 3 mg/kg 3 times a day).",
                        "html": "<p>1&#8239;mg/kg 3 times a day (max. per dose 3&#8239;mg/kg 3 times a day).</p>",
                        "ageGroup": "1&#8211;5 months"
                    },
                    {
                        "textContent": "2&#8211;4 mg/kg twice daily.",
                        "html": "<p>2&#8211;4&#8239;mg/kg twice daily.</p>",
                        "ageGroup": "6 months&#8211;2 years"
                    },
                    {
                        "textContent": "2&#8211;4 mg/kg twice daily (max. per dose 150 mg); increased to up to 5 mg/kg twice daily (max. per dose 300 mg), dose increase for severe gastro-oesophageal disease.",
                        "html": "<p>2&#8211;4&#8239;mg/kg twice daily (max. per dose 150&#8239;mg); increased to up to 5&#8239;mg/kg twice daily (max. per dose 300&#8239;mg), dose increase for severe gastro-oesophageal disease.</p>",
                        "ageGroup": "3&#8211;11 years"
                    },
                    {
                        "textContent": "150 mg twice daily, alternatively 300 mg once daily, dose to be taken at night, then increased if necessary to 300 mg twice daily for up to 12 weeks in moderate to severe gastro-oesophageal reflux disease, alternatively increased if necessary to 150 mg 4 times a day for up to 12 weeks in moderate to severe gastro-oesophageal reflux disease.",
                        "html": "<p>150&#8239;mg twice daily, alternatively 300&#8239;mg once daily, dose to be taken at night, then increased if necessary to 300&#8239;mg twice daily for up to 12 weeks in moderate to severe gastro-oesophageal reflux disease, alternatively increased if necessary to 150&#8239;mg 4 times a day for up to 12 weeks in moderate to severe gastro-oesophageal reflux disease.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Conditions where reduction of gastric acidity is beneficial and oral route not available",
                        "html": "Conditions where reduction of gastric acidity is beneficial and oral route not available"
                    }
                ],
                "specificity": {
                    "routes": [
                        "slow intravenous injection"
                    ],
                    "textContent": "By slow intravenous injection",
                    "html": "By slow intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "50 mg every 6&#8211;8 hours.",
                        "html": "<p>50&#8239;mg every 6&#8211;8&#8239;hours.</p>"
                    },
                    {
                        "textContent": "50 mg, dose to be diluted to 20 mL and given over at least 2 minutes; may be repeated every 6&#8211;8 hours.",
                        "html": "<p>50&#8239;mg, dose to be diluted to 20&#8239;mL and given over at least 2 minutes; may be repeated every 6&#8211;8 hours.</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "With oral use in children",
                    "html": "With <ph outputclass=\"route\">oral</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "oral"
                    ]
                },
                "textContent": "Oral preparations not licensed for use in children under 3 years.",
                "html": "<p>\n<i>Oral</i> preparations not licensed for use in children under 3 years. </p>"
            },
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "With intravenous use in children",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Injection not licensed for use in children under 6 months.",
                "html": "<p>\n<i>Injection</i> not licensed for use in children under 6 months.</p>"
            },
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "Doses given for prophylaxis of NSAID-associated gastric or duodenal ulcer, and prophylaxis of stress ulceration, are not licensed.",
                "html": "<p>Doses given for prophylaxis of NSAID-associated gastric or duodenal ulcer, and prophylaxis of stress ulceration, are not licensed.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (histamine H2-antagonists).",
                "html": "<p>Appendix 1 (histamine H<sub>2</sub>-antagonists).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Blurred vision",
                        "html": "Blurred vision",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "interstitial nephritis",
                        "html": "interstitial nephritis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "involuntary movement disorders",
                        "html": "involuntary movement disorders",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pancreatitis",
                        "html": "pancreatitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless essential, but not known to be harmful.",
                "html": "<p>Manufacturer advises avoid unless essential, but not known to be harmful.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Significant amount present in milk, but not known to be harmful.",
                "html": "<p>Significant amount present in milk, but not known to be harmful.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "Use half normal dose if eGFR less than 50 mL/minute/1.73 m2.",
                "html": "<p>Use half normal dose if eGFR less than 50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            },
            {
                "type": "doseAdjustments",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "Use half normal dose if estimated glomerular filtration rate less than 50 mL/minute/1.73 m 2.",
                "html": "<p>Use half normal dose if estimated glomerular filtration rate less than 50&#8239;mL/minute/1.73&#8239;m <sup>2</sup>.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in children",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For slow intravenous injection dilute to a concentration of 2.5 mg/mL with Glucose 5% or Sodium Chloride 0.9%; give over at least 3 minutes.",
                "html": "<p>For <i>slow intravenous injection</i> dilute to a concentration of 2.5&#8239;mg/mL with Glucose 5% or Sodium Chloride 0.9%; give over at least 3 minutes.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in adults",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in adults",
                    "patientType": "adults",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Zantac ), give intermittently in Glucose 5% or Sodium Chloride 0.9%.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Zantac</i>\n<tm tmtype=\"reg\"/>), give intermittently in Glucose 5% or Sodium Chloride 0.9%.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "references": [
                    {
                        "id": "http://www.medicinesforchildren.org.uk/ranitidine-for-acid-reflux",
                        "label": "www.medicinesforchildren.org.uk/ranitidine-for-acid-reflux"
                    }
                ],
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "title": "Medicines for Children leaflet: Ranitidine for acid reflux",
                "textContent": "www.medicinesforchildren.org.uk/ranitidine-for-acid-reflux",
                "html": "<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/ranitidine-for-acid-reflux\">www.medicinesforchildren.org.uk/ranitidine-for-acid-reflux</xref>\n</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "In fat malabsorption syndrome, give oral doses 1&#8211;2 hours before food to enhance effects of pancreatic enzyme replacement.",
                "html": "<p>In fat malabsorption syndrome, give oral doses 1&#8211;2 hours before food to enhance effects of pancreatic enzyme replacement.</p>"
            }
        ]
    },
    "exceptionsToLegalCategory": {
        "exceptionsToLegalCategory": [
            {
                "type": "exceptionsToLegalCategory",
                "textContent": "Ranitidine can be sold to the public for adults and children over 16 years (provided packs do not contain more than 2 weeks&#8217; supply) for the short-term symptomatic relief of heartburn, dyspepsia, and hyperacidity, and for the prevention of these symptoms when associated with consumption of food or drink (max. single dose 75 mg, max. daily dose 300 mg).",
                "html": "<p>Ranitidine can be sold to the public for adults and children over 16 years (provided packs do not contain more than 2 weeks&#8217; supply) for the short-term symptomatic relief of heartburn, dyspepsia, and hyperacidity, and for the prevention of these symptoms when associated with consumption of food or drink (max. single dose 75&#8239;mg, max. daily dose 300&#8239;mg).</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension",
                "oral solution",
                "infusion"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76490",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76643",
                "label": "Effervescent tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76799",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76567",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78174",
                "label": "Gastro-oesophageal reflux disease",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78207",
                "label": "Peptic ulceration",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_747",
                "label": "Ranitidine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34660",
                "label": "H2-RECEPTOR ANTAGONISTS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76490",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76643",
                "label": "Effervescent tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76799",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76567",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}